Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience.

Munteanu M; Ratziu V; Morra R; Messous D; Imbert-Bismut F; Poynard T

Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience.

Munteanu M, Ratziu V, Morra R, Messous D, Imbert-Bismut F …

MeSH — NLM indexing Biomarkers / blood Diagnosis, Differential Fatty Liver / blood Fatty Liver / complications Fatty Liver / diagnosis Hepatitis / blood Hepatitis / complications Hepatitis / diagnosis Humans Liver Cirrhosis / blood Liver Cirrhosis / complications Liver Cirrhosis / diagnosis Mass Screening / methods Metabolic Syndrome / blood Metabolic Syndrome / complications Risk Factors

Staff actions

Download PDF

Files are for authorised use within BioPredictive partner channels only.

Key publication Nash Fibrotest Review Our Group France

Authors (6)

Munteanu M — Biopredictive, and Groupe Hospitalier Pitié Salpêtrière, 47-83 Boulevard de l'Hopital, Paris, France. mona.munteanu@biopredictive.com
Ratziu V
Morra R
Messous D
Imbert-Bismut F

Munteanu M — Biopredictive, and Groupe Hospitalier Pitié Salpêtrière, 47-83 Boulevard de l'Hopital, Paris, France. mona.munteanu@biopredictive.com
Ratziu V
Morra R
Messous D
Imbert-Bismut F
Poynard T

Citation

Munteanu M, Ratziu V, Morra R, Messous D, Imbert-Bismut F, Poynard T. Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience. J Gastrointestin Liver Dis. 2008;17(2):187-91. PMID:18568141.

Identifiers

PMID: 18568141

Tests

Liver diseases

Liver injuries

Subjects

Risk factors

Region

Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients with metabolic risk factors: FibroTest-FibroMax experience.

More on the same topic

An Invisible Early Steatosis Phenotype Defined for a Large Population-Based Cohort.

Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.

Metabolic dysfunction-associated steatotic liver disease (MASLD) biomarkers and progression of lower limb arterial calcification in patients with type 2 diabetes: a prospective cohort study.

Noninvasive Assessment of Liver Fibrosis.

Screening for Metabolic Dysfunction-Associated Steatotic Liver Disease-Related Advanced Fibrosis in Diabetology: A Prospective Multicenter Study.

Three Neglected STARD Criteria Reduce the Uncertainty of the Liver Fibrosis Biomarker FibroTest-T2D in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD).